Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012; 119: 1981-7.
2. Baccarani M, Deininger MW, Rosti G, et al. ELN recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122: 872-83.
3. Pavlovsky C, Giere I, Moiraghi B, et al. Molecular monitoring to imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: Does achievement of a stable major molecular response (MMR) at any timepoint identify a privileged group of patients? A multicenter experience in Argentina and Uruguay. Clin Lymphoma Myeloma Leuk 2011; 11: 280-5.
4. Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-35.
5. Baccarani M, Cortés J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041-51.
6. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984; 63: 789-99.
7. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-55.
8. Lauseker M, Hanfstein B, Haferlach C, et al. Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase. J Cancer Res Clin Oncol 2014; 140: 1965-9.
9. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia 2003; 17: 2318-57.
10. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37.
11. Cross NC, White HE, Colomer D, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 2015; 29: 999-1003.
12. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. En: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf; consultado el 18/8/2016.
13. Hjorth-Hansen H, Stenke L, Soderlund S, et al. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol 2015; 94: 243-50.
14. Jain P, Kantarjian H, Alattar ML, et al. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase Chronic Myeloid Leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol 2015; 3: 118-28.
15. Lang AS, Mounier M, Roques M, Chretien ML, Boulin M. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in Chronic Myeloid Leukemia over a period of more than 10 years. J Clin Pharm Ther 2015; 4: 391-7.
16. Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 2015; 5: 1123-32.
17. Castagnetti F, Gugliotta G, Breccia M, et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia 2015; 9: 1823-31.
18. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010; 19: 3758-65.
19. Hehlmann R, Müller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 2014; 32: 415-23.
20. Nazha A, Kantarjian H, Jain P, et al. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica 2013; 98: 1686-8.
21. Branford S, Roberts N, Yeung DT, Altamura H, Parker WT, Hughes TH. Any BCR-ABL reduction below 10% at 6 months of therapy significantly improves outcome for CML patients with a poor response at 3 months. ASH annual meeting 2013; session 632: abstract 254. En: http://www.bloodjournal.org/content/122/21/254; consultado el 11/11/2016.
22. Hughes TP, Hochhaus A, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-32.
23. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29: 1634-42.
24. O’Brien S, Radich JP, Abboud CN, et al. Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw 2014; 12: 1590-610.
25. Saussele S, Hehlmann R, Dietz C, et al. Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML-study IV. ASH Annual Meeting 2014; session 632: abstract 155. En: http://www.bloodjournal.org/content/124/21/155; consultado el 11/11/2016.